Literature DB >> 15644401

Year of diagnosis, features at presentation, and risk of recurrence in patients with pheochromocytoma or secreting paraganglioma.

Laurence Amar1, Aude Servais, Anne-Paule Gimenez-Roqueplo, Franck Zinzindohoue, Gilles Chatellier, Pierre-François Plouin.   

Abstract

Pheochromocytoma or secreting paraganglioma may recur after initial surgery. Diagnostic methods have improved in recent decades. We determined whether features at presentation have changed over time and are associated with long-term outcome. In 192 patients with pheochromocytoma/paraganglioma seen between 1975 and 2003, we compared time from onset of hypertension to first operation, total metanephrine excretion, tumor size and site, the proportion of cases presenting as incidentalomas, and the probability of recurrence according to date of operation (divided into quartiles). The duration of hypertension and tumor size at first operation decreased significantly over time. Right-sided adrenal tumors were more frequent and larger, excreted greater amounts of metanephrines, and presented more frequently as incidentalomas than left-sided tumors. Age, familial disease, and tumor site and size were independent predictors of recurrence. The risk of recurrence was 3.4-fold higher in patients with familial disease than in those with sporadic tumors; it was, respectively, 3.1- and 11.2-fold higher in patients with right adrenal and extraadrenal tumors than in patients with left adrenal tumors. In conclusion, pheochromocytomas/paragangliomas can now be diagnosed earlier, with smaller tumors, and more frequently as incidentalomas. Familial, right adrenal, and extraadrenal tumors recur more frequently than left adrenal tumors.

Entities:  

Mesh:

Year:  2005        PMID: 15644401     DOI: 10.1210/jc.2004-1398

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  98 in total

Review 1.  Emerging role of dopamine in neovascularization of pheochromocytoma and paraganglioma.

Authors:  Thamara E Osinga; Thera P Links; Robin P F Dullaart; Karel Pacak; Anouk N A van der Horst-Schrivers; Michiel N Kerstens; Ido P Kema
Journal:  FASEB J       Date:  2017-03-06       Impact factor: 5.191

Review 2.  Percutaneous ablation of adrenal tumors.

Authors:  Aradhana M Venkatesan; Julia Locklin; Damian E Dupuy; Bradford J Wood
Journal:  Tech Vasc Interv Radiol       Date:  2010-06

3.  Clinically silent chromaffin-cell tumors: Tumor characteristics and long-term prognosis in patients with incidentally discovered pheochromocytomas.

Authors:  S Grozinsky-Glasberg; A Szalat; C A Benbassat; A Gorshtein; R Weinstein; D Hirsch; I Shraga-Slutzky; G Tsvetov; D J Gross; I Shimon
Journal:  J Endocrinol Invest       Date:  2010-05-17       Impact factor: 4.256

4.  Laparoscopic management of recurrent pheochromocytoma: A case report.

Authors:  Harshit Garg; Manpreet Uppal; Sreesanth Kelu Sreedharan; Sandeep Aggarwal
Journal:  J Minim Access Surg       Date:  2016 Jul-Sep       Impact factor: 1.407

Review 5.  A review on the clinical uses of SPECT/CT.

Authors:  Giuliano Mariani; Laura Bruselli; Torsten Kuwert; Edmund E Kim; Albert Flotats; Ora Israel; Maurizio Dondi; Naoyuki Watanabe
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-02-25       Impact factor: 9.236

6.  [An incidental finding of retrocaval extraadrenal pheochromocytoma].

Authors:  Katharina Maria Bretterbauer; Daniela Colleselli; Ahmed Magdy; Günter Janetschek; Michael Mitterberger
Journal:  Wien Med Wochenschr       Date:  2015-07-14

7.  Robotic approach for partial adrenalectomy.

Authors:  Benedetto Calì; Claire Nomine-Criqui; Florence Bihain; Laurent Brunaud
Journal:  Updates Surg       Date:  2021-01-07

8.  Catecholamine-secreting paragangliomas: recent progress in diagnosis and perioperative management.

Authors:  Tahl Y Colen; Frederick G Mihm; Theodore P Mason; Joseph B Roberson
Journal:  Skull Base       Date:  2009-11

Review 9.  Current and future treatments for malignant pheochromocytoma and sympathetic paraganglioma.

Authors:  Camilo Jimenez; Eric Rohren; Mouhammed Amir Habra; Thereasa Rich; Paola Jimenez; Montserrat Ayala-Ramirez; Eric Baudin
Journal:  Curr Oncol Rep       Date:  2013-08       Impact factor: 5.075

10.  Penetrance and clinical consequences of a gross SDHB deletion in a large family.

Authors:  D C Solis; N Burnichon; H J L M Timmers; M J Raygada; A Kozupa; M J Merino; D Makey; K T Adams; A Venisse; A-P Gimenez-Roqueplo; K Pacak
Journal:  Clin Genet       Date:  2009-04       Impact factor: 4.438

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.